$Pfizer(PFE)$ the biggest clue

2023-04-28

$Pfizer(PFE)$ the biggest clue about Pfizer's upcoming quarter is today's $Merck(MRK)$ earnings

MRK saw a huge decline in its COVID related therapy. For PFE is probably going to be much greater since plaxovid was better than MRK Molnupiravir, but without hikes in covid cases, it is doubtful plaxovid will be bringing enough sales for a big surprise. I have PFE on watch for a possibility of long if there is a good decline towards $30-$36 post its earnings report. Then start to rebuild a position in it.

Their COVID bonanza brought them a ton of cash which it has used to buy firm after firm to replace the patent cliff of meds (a problem it had pre pandemic), but the firms it has bought are not likely to bring cash to the bottom line this quarter. The risky of this part is that Bourla may pumps the forecasts instead of the current quarter and market doesn't pay attention to the quarter that is being reported (priced in?) and instead focus on the future.

Still it is best to wait for the ER.

US Stocks Opportunities

Here are a theme that collects the best quality or your most bullish US stocks, Share your thoughts here!

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":9947376914,"tweetId":"9947376914","gmtCreate":1682613479139,"gmtModify":1682613483711,"author":{"id":9000000000000427,"authorId":9000000000000427,"authorIdStr":"9000000000000427","name":"PenelopeHood","avatar":"https://static.tigerbbs.com/5db4d62c071dcb2907bb17a6acb6ce29","vip":8,"userType":8,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[{"themeId":"84ac2c57901b463da0573a608cc0b2a5","categoryId":"7cf744760f454845a1870a05ea4e151d","name":"US Stocks Opportunities","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":84ac2c57901b463da0573a608cc0b2a5}&rnconfig={\"headerBarHidden\": true}","description":"Here are a theme that collects the best quality or your most bullish US stocks, Share your thoughts here!","image":"https://static.tigerbbs.com/09d268d2d1fb9f45eacf5430006f3845"}],"images":[],"coverImages":[],"html":"<html><head></head><body> <a data-mention-id=\"PFE\" class=\"teditor-mention\" data-mention-name=\"Pfizer\" href=\"https://ttm.financial/S/PFE\">$Pfizer(PFE)$</a> the biggest clue about Pfizer's upcoming quarter is today's <a data-mention-id=\"MRK\" class=\"teditor-mention\" data-mention-name=\"Merck\" href=\"https://ttm.financial/S/MRK\">$Merck(MRK)$</a> earnings MRK saw a huge decline in its COVID related therapy. For PFE is probably going to be much greater since plaxovid was better than MRK Molnupiravir, but without hikes in covid cases, it is doubtful plaxovid will be bringing enough sales for a big surprise. I have PFE on watch for a possibility of long if there is a good decline towards $30-$36 post its earnings report. Then start to rebuild a position in it. Their COVID bonanza brought them a ton of cash which it has used to buy firm after firm to replace the patent cliff of meds (a problem it had pre pandemic), but the firms it has bought are not likely to bring cash to the bottom line this quarter. The risky of this part is that Bourla may pumps the forecasts instead of the current quarter and market doesn't pay attention to the quarter that is being reported (priced in?) and instead focus on the future. Still it is best to wait for the ER.</body></html>","htmlText":"<html><head></head><body> <a data-mention-id=\"PFE\" class=\"teditor-mention\" data-mention-name=\"Pfizer\" href=\"https://ttm.financial/S/PFE\">$Pfizer(PFE)$</a> the biggest clue about Pfizer's upcoming quarter is today's <a data-mention-id=\"MRK\" class=\"teditor-mention\" data-mention-name=\"Merck\" href=\"https://ttm.financial/S/MRK\">$Merck(MRK)$</a> earnings MRK saw a huge decline in its COVID related therapy. For PFE is probably going to be much greater since plaxovid was better than MRK Molnupiravir, but without hikes in covid cases, it is doubtful plaxovid will be bringing enough sales for a big surprise. I have PFE on watch for a possibility of long if there is a good decline towards $30-$36 post its earnings report. Then start to rebuild a position in it. Their COVID bonanza brought them a ton of cash which it has used to buy firm after firm to replace the patent cliff of meds (a problem it had pre pandemic), but the firms it has bought are not likely to bring cash to the bottom line this quarter. The risky of this part is that Bourla may pumps the forecasts instead of the current quarter and market doesn't pay attention to the quarter that is being reported (priced in?) and instead focus on the future. Still it is best to wait for the ER.</body></html>","text":"$Pfizer(PFE)$ the biggest clue about Pfizer's upcoming quarter is today's $Merck(MRK)$ earnings MRK saw a huge decline in its COVID related therapy. For PFE is probably going to be much greater since plaxovid was better than MRK Molnupiravir, but without hikes in covid cases, it is doubtful plaxovid will be bringing enough sales for a big surprise. I have PFE on watch for a possibility of long if there is a good decline towards $30-$36 post its earnings report. Then start to rebuild a position in it. Their COVID bonanza brought them a ton of cash which it has used to buy firm after firm to replace the patent cliff of meds (a problem it had pre pandemic), but the firms it has bought are not likely to bring cash to the bottom line this quarter. The risky of this part is that Bourla may pumps the forecasts instead of the current quarter and market doesn't pay attention to the quarter that is being reported (priced in?) and instead focus on the future. Still it is best to wait for the ER.","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9947376914","repostId":0,"isVote":1,"tweetType":1,"viewCount":369,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["MRK","PFE"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":818,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/9947376914"}